Loading…
S. 545119th CongressPlaced on the calendarLatest action Apr 15, 2026Decoded by AI · checked against the record
The plain-language version leads. The official text is always the reference.
Senate bill S 545 would place xylazine on Schedule III of the Controlled Substances Act, adding federal tracking, storage, and distribution rules.
55-second read · 4 questions answered below
S 545 would add xylazine, an animal sedative increasingly mixed into illegal drugs like fentanyl, to Schedule III of the Controlled Substances Act, the same category as anabolic steroids and some prescription medications. Legitimate veterinary use, pharmacy dispensing, and legal use in wildlife and government animal control programs would remain permitted. Manufacturers would have up to one year to meet new labeling and packaging requirements and 60 days to register under the new rules.
The bill primarily affects veterinarians, pharmacies, and drug manufacturers who use or produce xylazine legally. It also affects law enforcement and people involved in the illegal drug supply chain.
Placing xylazine on Schedule III would impose federal rules on how it is tracked, stored, and distributed, and could alter criminal exposure for those trafficking it illegally. The DEA and FDA would be required to report to Congress within 18 months on how xylazine is being diverted and where it originates, with a follow-up report due in four years.
AI-drafted summary. Verify it against the official text before you act on it. Read the official bill on Congress.gov
Right now: it was placed on the Senate floor calendar, and the official record shows no floor action on it since. If the House changes it, it goes back to the Senate before reaching the President.
Latest action: — Placed on Senate Legislative Calendar under General Orders. Calendar No. 372.